top of page
MONITORING LIFE SA COMO EMPRESA EMERGENTE (STARTUP), CONFORME A LA LEY 28/2022, DE 21 DE DICIEMBRE, DE FOMENTO DEL ECOSISTEMA DE LAS EMPRESAS EMERGENTES.
.png){kind=small}
is the world’s first multimodal sensor for home monitoring of heart failure decompensations that uniquely integrates ECG, PCG, and PPG signals in a single device
Sensocor ML continuous monitoring enables assessment of the heart’s electrical, mechanical, and hemodynamic activity, including left ventricular ejection function. Data are securely transmitted to a clinical platform that supports early detection of decompensation and earlier clinical intervention
​
CLINICIANS
Access reliable, clinically meaningful information that reduces workload and improves outcomes
PATIENTS
Experience fewer hospitalizations and visits, easing the burden on themselves and their families
PUBLIC-PRIVATE HEALTHCARE SYSTEM & INSURERS
Delivers greater sustainability, cost savings, reduced care burden, lower environmental impact and patient experience
Clinical Evidence
2023 - First Clinical Trial
2025 - 150 patients Clinical Trial for CE mark approval
2026 - Clinical trial in real use: Home-Based study
bottom of page